Outcomes of SMARCB1-deficient sinonasal carcinoma: Largest single-center cross-sectional study.

ABSTRACT:

Background

We evaluate outcomes of SMARCB1-deficient sinonasal carcinomas in the largest single-institution study.

Methods

Retrospective cross-sectional study of patients with SMARCB1-deficient sinonasal carcinoma between 1998 and 2024. Disease-specific survival (DSS) and recurrence-free probability (RFP) at 1 and 5 years were measured by Kaplan-Meier method.

Results

There were 47 patients with a median age of 53. Initial pathological diagnosis was altered in 33%. Twelve (34%) patients received neoadjuvant chemotherapy, with one partial response. Curative surgical approach was undertaken in 73%. Definitive chemoradiation was administered in 20%. DSS at 1 and 5 years was 93% and 45%, respectively. RFP at 1 and 5 years was 73% and 33%, respectively. On multivariate anal

SUBMITTER: Woods R 

PROVIDER: S-EPMC12404152 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature